Challenging Cases: When and How to Use GLP-1 Agonists in Diabetes Management- CEU 2019 Seattle

Seattle, WA US

Saturday, September 21, 2019
Hyatt Regency, Regency Ballroom  
Program: 12:15 – 1:15 pm

This course is a live CME-certified Ancillary Symposium presented at CEU 2019, held in Seattle, WA. This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. These ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).

 

PLEASE REGISTER THEN CLICK "START" TO:

  • TAKE PRE-SURVEY

  • EVALUATE SESSIONS

  • CLAIM CME

  • DOWNLOAD PRESENTATION SLIDES

  • PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION

 

Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Apply guidelines and algorithms on the initiation and treatment of pharmacotherapies for the management of type 2 diabetes.
  • Devise individualized initiation and treatment plans for patients with type 2 diabetes that incorporates updated clinical information on GLP-1 agonist options and take into consideration indications, safety, and efficacy as well as diabetes complications or significant risk factors.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
09/21/2019
Course expires: 
12/31/2019
Hyatt Regency Seattle, Regency Ballroom
808 Howell Street
Seattle, WA 98101
United States

Program Co-Chairs

Carol Wysham, MD
Section Head
Rockwood Center
Clinical Associate Professor
University of Washington
Spokane, WA

Marie E. McDonnell, MD
Diabetes Section Chief
Brigham and Women’s Hospital
Harvard University
Boston, MA

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following patient representative reported no relevant financial relationships during the content development process for this activity: Marie E. McDonnell, MD (Chair)

The faculty reported the following relevant financial relationship(s) during the content development process for this activity: 
Carol Wysham, MD (Chair): Consulting, AstraZeneca, Abbott, Janssen, Novo Nordisk, Sanofi, Boehringer Ingelheim; Speaker, AstraZeneca, Abbott, Janssen, Novo Nordisk, Sanofi, Boehringer Ingelheim; Research support, Abbott, Novo Nordisk, Mylan, Lilly  

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Ann Casey, MD

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

 

USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.

Click "Start" to complete the meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
 
The Endocrine Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™ and 1.0 ABIM MOC Point. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact

 

MAINTENANCE OF CERTIFICATION 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

 

Review your Diplomate ABIM ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
PLEASE CLICK "START" FOR THE FOLLOWING ACTION:
 
  • TAKE PRE-SURVEY
  • EVALUATE SESSIONS
  • CLAIM CME
  • DOWNLOAD PRESENTATION SLIDES
  • PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION